Sign in

    James Creedy

    Research Analyst at Goldman Sachs Group Inc.

    James Creedy is an analyst at Goldman Sachs Group Inc., specializing in equity research with a primary focus on European banks and financial institutions. He has covered leading companies such as Barclays, HSBC, UBS, and Credit Suisse, establishing a reputation for grounded sector insights and timely investment recommendations. With a background in financial analysis that began in the early 2010s and experience at both boutique research firms and larger investment banks prior to joining Goldman Sachs, Creedy has consistently delivered robust returns and actionable calls, achieving success rates above sector benchmarks and recognition within industry rankings. He holds FINRA Series 7 and 63 licenses and is known for integrating macroeconomic risk analysis into company-level coverage to drive outperformance.

    James Creedy's questions to NOVO NORDISK A S (NVO) leadership

    James Creedy's questions to NOVO NORDISK A S (NVO) leadership • Q1 2024

    Question

    James Creedy asked about the clinical view on desirable fat-to-muscle loss ratios during weight loss and whether data from the SELECT trial indicated any changes in lean body mass composition over time.

    Answer

    Martin Lange, Head of R&D, explained that physicians generally consider the observed lean mass loss (35-40%) to be within a normal and healthy range for significant weight loss. He cited the positive all-cause mortality data from SELECT as evidence of a healthy weight loss profile and stated he had no specific body composition data from the trial to share.

    Ask Fintool Equity Research AI